Pimecrolimus cream 1% vs. betamethasone 17-valerate 0.1% cream in the treatment of seborrhoeic dermatitis. A randomized open-label clinical trial

British Journal of Dermatology

Volumn 151, Issue 5, 2004, Pages 1071-1075

  Rigopoulos, D ^a   Ioannides, D ^b   Kalogeromitros, D ^a   Gregoriou, S ^a   Katsambas, A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Betamethasone 17 valerate; Pimecrolimus; Seborrhoeic dermatitis

Indexed keywords

BETAMETHASONE VALERATE; CORTICOSTEROID; PIMECROLIMUS;

ADULT; ARTICLE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SEBORRHEIC DERMATITIS; SIDE EFFECT; SKIN ATROPHY; TELANGIECTASIA;

ADMINISTRATION, CUTANEOUS; ADULT; BETAMETHASONE; CALCINEURIN; DERMATITIS, SEBORRHEIC; DERMATOLOGIC AGENTS; ERYTHEMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PRURITUS; RECURRENCE; SEVERITY OF ILLNESS INDEX; TACROLIMUS; TREATMENT OUTCOME;

EID: 9644257237     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.06208.x     Document Type: Article

References (5)

1. Dupuy P, Maurette C, Amoric JC, Chosidow O and the Study Investigator Group. Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis. Br J Dermatol 2001; 144: 1033-7.
2. Meingassner JG, Grassberger M, Fahrgruber H et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997; 137: 568-76.
3. Crutchfield CE. Pimecrolimus: a new treatment for seborrheic dermatitis. Cutis 2002; 70; 207-8.
4. Queille-Roussel C, Paul C, Duteil L et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001; 144: 507-13.
5. Braza TJ, DiCarlo JB, Soon SL, McCall CO. Tacrolimus 0.1% ointment for seborrhoeic dermatitis: an open-label pilot study. Br J Dermatol 2003; 148: 1242-4.